[email protected]

01252 375362

01252 375362

  • About Us
    • About Pharmacy Consulting
    • Our Team
    • Work with us
    • Testimonials
  • Consultancy
    • For Pharmaceutical Wholesalers
    • For Pharmacies
    • Care Quality Commission – CQC
    • Pharmaceutical Manufacturers
    • Medical Devices Consultancy and Training
  • Flexible Training
    • Good Distribution Practice (GDP) Training
    • RPi Training
    • Licence Holder Training
    • Export Training
    • Audit Training
    • Active Pharmaceutical Ingredient (API) and Clinical Trials Training
    • Superintendent Pharmacist Training
    • GPhC Guidance for Online Pharmacies
  • RP Cogent GDP Training
  • RP Forum
  • Training Calendar
  • Our CPD
    • Blog
    • Editorial Items
    • Social Media
  • Contact Us
MHRA Response to contaminated paediatric medicines

MHRA Response to contaminated paediatric medicines

by Amelia Holmes | Oct 27, 2022 | Blog, GDP/RP, Good Distribution Practice - GDP, MHRA, Training

On the 7th of October The Medicines and Healthcare products Regulatory Agency (MHRA) released a response to contaminated paediatric medicines identified by the WHO region of Africa.

The Canada – United Kingdom Trade Continuity Agreement (CUK TCA) Protocol

The Canada – United Kingdom Trade Continuity Agreement (CUK TCA) Protocol

by Amelia Holmes | Sep 26, 2022 | Blog

The Canada – United Kingdom Trade Continuity Agreement (CUK TCA) was entered into force on the 1st of April 2021.

Defective Medicinal Products and Recall Management Guidance

Defective Medicinal Products and Recall Management Guidance

by Amelia Holmes | Aug 5, 2022 | Blog, MHRA

The main concerns with regard to possible defects of medicinal products and the substances used in their manufacture or packaging.

Import Licensed Human Medicine(s) to the United Kingdom (UK) – Guidance

Import Licensed Human Medicine(s) to the United Kingdom (UK) – Guidance

by Amelia Holmes | Jul 13, 2022 | Blog, MHRA, WDA(H), WDA(H)

Import Licensed Human Medicine – Prior to importation of a licensed medicine applications for the relevant Licence(s) must be completed and submitted which may include one or more of the following:

Import Unlicensed Human Medicine(s) to the United Kingdom (UK) – guidance

Import Unlicensed Human Medicine(s) to the United Kingdom (UK) – guidance

by Amelia Holmes | Jul 13, 2022 | Blog, Good Distribution Practice - GDP, MHRA, WDA(H)

An Introduced Product is an unlicensed medicine which can be imported from a country other than an approved country for import to be exported to a country other than an approved country for import, or if imported from a non-EEA country into Northern Ireland for export back to a country outside the EEA.

« Older Entries
Next Entries »

Recent Posts

  • Journalists – Be Careful What You Write About Medicines
  • Responsible Person for Import Role after the Windsor Framework
  • Emerging Risks in Pharmacy Practice: Key Updates from the GPhC

Upcoming Courses

  • RP Forum – Good Documentation Practice on 13 May 2025 10:00 am
  • Export Online Training on 14 May 2025
  • GDP/RP Cogent Gold Standard Online Training on 20 May 2025
  • Introduction to Good Distribution Practice Online Training on 28 May 2025 10:00 am
  • Licence Holder Training on 10 June 2025 10:00 am

MHRA Alerts & Recalls

Field Safety Notices: 28 October to 1 November 2024
8 May 2025
Class 4 Medicines Defect Notification: Chloramphenicol 1% w/w Eye Ointment, Blumont Pharma Limited, EL(25)A/20
8 May 2025
Field Safety Notices: 28 April to 2 May 2025
6 May 2025
MHRA Safety Roundup: April 2025
29 April 2025

Get In Touch

Address:
Wellesley House
10 Eelmoor Road
Farnborough
Hampshire
GU14 7QN

Phone: 01252 375362
Email: [email protected]
  • Terms and Conditions
  • Privacy Policy

Designed by Four Lakes

  • Follow
  • Follow
  • Follow
  • Follow